Qure.ai's AI X-ray for Lung Nodules Gets USFDA Clearance
Qure.ai's AI-powered chest X-ray solution for lung nodule detection receives USFDA clearance, marking the company's 6th clearance for chest X-ray solutions.

New Delhi, Jan 10 (PTI) Medical imaging solutions provider Qure.ai on Wednesday said it has received clearance from US health regulator for its artificial intelligence-enabled X-ray for detection of lung nodules.
Qure's chest X-ray-based qXR-LN uses artificial intelligence (AI)to identify and localize lung nodules thereby helping in identifying potentially malignant pulmonary nodules, thus boosting the fight against lung cancer, the company said in a statement.
This also marks the 6th USFDA (United States Food and Drug Administration) clearance for Qure's chest X-ray based solutions, the company said.
The qXR for lung nodule is a cutting-edge detection software designed to identify and highlight regions indicative of suspected pulmonary nodules ranging from 6 to 30 mm in size.
Prashant Warier, Co-Founder and CEO of Qure.ai, said the company has already deployed and implemented this solution globally, and the USFDA clearance "marks yet another ground-breaking leap in our pioneering efforts to combat lung cancer".
"Our heightened emphasis on the North American marketplace solidifies our commitment to making a meaningful impact in the fight against this deadly disease and underscores our dedication to advancing healthcare through innovation, providing a transformative solution enhancing the early detection of cancer and ultimately improving patient outcomes," Warier said.
Qure's chest X-ray-based qXR-LN uses artificial intelligence (AI)to identify and localize lung nodules thereby helping in identifying potentially malignant pulmonary nodules, thus boosting the fight against lung cancer, the company said in a statement.
This also marks the 6th USFDA (United States Food and Drug Administration) clearance for Qure's chest X-ray based solutions, the company said.
The qXR for lung nodule is a cutting-edge detection software designed to identify and highlight regions indicative of suspected pulmonary nodules ranging from 6 to 30 mm in size.
Prashant Warier, Co-Founder and CEO of Qure.ai, said the company has already deployed and implemented this solution globally, and the USFDA clearance "marks yet another ground-breaking leap in our pioneering efforts to combat lung cancer".
"Our heightened emphasis on the North American marketplace solidifies our commitment to making a meaningful impact in the fight against this deadly disease and underscores our dedication to advancing healthcare through innovation, providing a transformative solution enhancing the early detection of cancer and ultimately improving patient outcomes," Warier said.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone-Idea-L
- 10.80 (+ 1.12)
- 64479733
- Pradhin
- 0.27 (+ 17.39)
- 41923542
- Sattva-Sukun-Lifecar
- 0.56 (+ 5.66)
- 34488002
- Alstone-Textiles
- 0.30 ( 0.00)
- 34091490
- Sunshine-Capital
- 0.25 ( -3.85)
- 30901660





